Search
Baike Biotech Secures Approval for Clinical Trial of Recombinant Zoster Vaccine
2025-06-04 /
Read about 0 minute
Author：小编
Baike Biotech has garnered approval from the National Medical Products Administration to initiate clinical trials for a recombinant zoster vaccine aimed at preventing shingles in adults aged 40 and older. Should the vaccine successfully come to market, it will not only diversify the company's product portfolio but also bolster its profitability. Nevertheless, the clinical trial and commercialization process remain uncertain, and thus, this development is not anticipated to have a material impact on the company's near-term performance.
-
C114 Communication Network -
Communication Home
7 X 24 Track global technological trends
